Immatics at the ASCO Annual Meeting 2018 (June 1-5) in Chicago, IL
Immatics at ASCO Annual Meeting, June 1-5 in Chicago! If you're there take the chance to discuss cancer care treatment and partnering options with present Senior Management and other experts from Immatics.
Don't miss out on results from the GAPVAC clinical trial:
The poster presentation "Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers" (Poster Board #317b, Abstract #TPS3106) by Dr Apostolia Maria Tsimberidou and colleagues from MD Anderson Cancer Center and Immatics will take place on June 4th during the Developmental Therapeutics—Immunotherapy Poster Session (starting 8:00 am CDT, Hall A).
IMA101 is a personalized, multi-targeted investigational immunotherapy for the treatment of multiple solid tumors, including but not limited to ovarian cancer, gastric cancer, esophageal cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer. The single-center study is open for enrollment at The University of Texas MD Anderson Cancer Center in Houston, Texas.
Further information on ASCO here.